Metabolic syndrome in bipolar disorders

Indian Journal of Psychological Medicine

Volumn 34, Issue 2, 2012, Pages 110-118

  Chakrabarti, Subho ^a   Grover, Sandeep ^a   Kulhara, Parmanand ^a   Malhotra, Nidhi ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Bipolar disorders; Diabetes mellitus; Metabolic syndrome; Obesity; Prevalence

Indexed keywords

EID: 84867340694     PISSN: 02537176     EISSN: 09751564     Source Type: Journal    
DOI: 10.4103/0253-7176.101767     Document Type: Review

References (84)

1. Osby U, Brandt L, Correia N, Ekbom A, Sparen P. Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry 2001;58:844-50
2. Ng F, Mammen OK, Wilting I, Sachs GS, Ferrier IN, Cassidy F, et al. The International Society for Bipolar Disorders (ISBD) consensus guidelines for the safety monitoring of bipolar disorder treatments. Bipolar Disord 2009;11:559-95
3. Elmslie JL, Mann JI, Silverstone JT, Williams SM, Romans SE. Determinants of overweight and obesity in patients with bipolar disorder. J Clin Psychiatry 2001;62:486-91
4. Waxmonsky JA, Thomas MR, Miklowitz DJ, Allen MH, Wisniewski SR, Zhang H, et al. Prevalence and correlates of tobacco use in bipolar disorder: Data from the first 2000 participants in the systematic treatment enhancement program. Gen Hosp Psychiatry 2005;27:321-8
5. Lakka TA, Bouchard C. Physical activity, obesity and cardiovascular diseases. Handb Exp Pharmacol 2005;170:137- 63
6. Ford ES, Kohl III HW, Mokdad AH, Ajani UA. Sedentary behavior, physical activity, and the metabolic syndrome among U.S. adults. Obesity Res 2005;13:608-14
7. Meyer JM. A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapinetreated inpatients: metabolic outcomes after 1 year. J Clin Psychiatry 2002;63:425-33
8. Guo JJ, Keck PE, Corey-Lisle PK, Li H, Jiang D, Jang R, et al. Risk of diabetes mellitus associated with atypical antipsychotic use among patients with bipolar disorder: A retrospective, population-based, case-control study. J Clin Psychiatry 2006;67:1055-61
9. Fagiolini A, Chengappa KN, Soreca I, Chang J. Bipolar disorder and the metabolic syndrome: causal factors, psychiatric outcomes and economic burden. CNS Drugs 2008;22:655-69
10. Taylor V, MacQueen G. Associations between bipolar disorder and metabolic syndrome: A review. J Clin Psychiatry 2006;67:1034-41
11. Fagiolini A, Frank E, Houck PR, Mallinger AG, Swartz HA, Buysse DJ, et al. Prevalence of obesity and weight change during treatment in patients with bipolar I disorder. J Clin Psychiatry 2002;63:528-33
12. Fagiolini A, Kupfer DJ, Houck PR, Novick DM, Frank E. Obesity as a correlate of outcome in patients with bipolar I disorder. Am J Psychiatry 2003;160:112-17
13. McElroy SL, Kotwal R, Malhotra S, Nelson EB, Keck PE, Nemeroff CB. Are mood disorders and obesity related? A review for the mental health professional. J Clin Psychiatry 2004;65:634-51
14. Keck PE, McElroy SL. Bipolar disorder, obesity, and pharmacotherapy- associated weight gain. J Clin Psychiatry 2003;64:1426-35
15. McElroy SL, Frye MA, Suppes T, Dhavale D, Keck PE Jr, Leverich GS, et al. Correlates of overweight and obesity in 644 patients with bipolar disorder. J Clin Psychiatry 2002;63:207-13
16. Nemeroff CB. Safety of available agents used to treat bipolar disorder: focus on weight gain. J Clin Psychiatry 2003;64:532-39
17. Elmslie JL, Silverstone JT, Mann JI, Williams SM, Romans SE. Prevalence of overweight and obesity in bipolar patients. J Clin Psychiatry 2000;61:179-84
18. Kilbourne AM, Cornelius JR, Han X, Pincus HA, Shad M, Salloum I, et al. Burden of general medical conditions among individuals with bipolar disorder. Bipolar Disord 2004;6:368- 73
19. Ruzickova M, Slaney C, Garnham J, Alda M. Clinical features of bipolar disorder with and without comorbid diabetes mellitus. Can J Psychiatry 2003;48:458-61
20. Regenold WT, Thapar RK, Marano C, Gavirneni S, Kondapavuluru PV. Increased prevalence of type 2 diabetes mellitus among psychiatric inpatients with bipolar I affective and schizoaffective disorders independent of psychotropic drug use. J Affect Disord 2002;70:19-26
21. Cassidy F, Ahearn E, Carroll BJ. Elevated frequency of diabetes mellitus in hospitalized manic-depressive patients. Am J Psychiatry 1999;156:1417-20
22. Russell JD, Johnson GF. Affective disorders, diabetes mellitus and lithium. Aust NZ J Psychiatry 1981;15:349-53
23. Lilliker SL. Prevalence of diabetes in a manic-depressive population. Compr Psychiatry 1980;21:270-75
24. Sobczak S, Honig A, Christophe A, Maes M, Helsdingen RW, De Vriese SA, et al. Lower high density lipoprotein cholesterol and increased omega-6 polyunsaturated fatty acids in first-degree relatives of bipolar patients. Psychol Med 2004;34:103-12
25. Atmaca M, Kuloglu M, Tezcan E, Ustundag B, Bayik Y. Serum leptin and cholesterol levels in patients with bipolar disorder. Neuropsychobiology 2002;46:176-9
26. Horrobin DF, Bennett CN. Depression and bipolar disorder: relationships to impaired fatty acid and phospholipid metabolism and to diabetes, cardiovascular disease, immunological abnormalities, cancer, ageing and osteoporosis. Possible candidate genes. Prostaglandins Leukot Essent Fatty Acids 1999;60:217-34
27. Yates WR, Wallace R. Cardiovascular risk factors in affective disorder. J Affect Disord 1987;12:129-34
28. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications. Report of a WHO consultation. Geneva: World Health Organisation; 1999
29. Balkau B, Charles MA. Comment on the provisional report from the WHO consultation. Diabet Med 1999;16:442-3
30. Alberti KG, Zimmet PZ, Shaw J. Metabolic syndrome-a new worldwide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med 2006;23:469-80
31. National Cholesterol Education Program. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97
32. American College of Endocrinology Task Force on the Insulin Resistance Syndrome. Endocr Pract 2003;9:236-52
33. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C. American Heart Association; National Heart, Lung, and Blood Institute. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/ American Heart Association conference on scientific issues related to definition. Circulation 2004;109:433-8
34. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009;120:1640-5
35. Simmons RK, Alberti KG, Gale EA, Colagiuri S, Tuomilehto J, Qiao Q, et al. The metabolic syndrome: Useful concept or clinical tool? Report of a WHO Expert Consultation. Diabetologia 2010;53:600-5
36. Basu R, Brar JS, Chengappa KN, John V, Parepally H, Gershon S, et al. The prevalence of the metabolic syndrome in patients with schizoaffective disorder - bipolar subtype. Bipolar Disord 2004;6:314-8
37. Birkenaes AB, Søgaard AJ, Engh JA, Jonsdottir H, Ringen PA, Vaskinn A, et al. Sociodemographic characteristics and cardiovascular risk factors in patients with severe mental disorders compared with the general population. J Clin Psychiatry 2006;67:425-33
38. Cardenas J, Frye MA, Marusak SL, Levander EM, Chirichigno JW, Lewis S, et al. Modal subcomponents of metabolic syndrome in patients with bipolar disorder. J Affect Disord 2008;106:91-7
39. Chang HH, Chou CH, Chen PS, Gean PW, Huang HC, Lin CY, et al. High prevalence of metabolic disturbances in patients with bipolar disorder in Taiwan. J Affect Disord 2009;117:124-9
40. Correll CU, Frederickson AM, Kane JM, Manu P. Equally increased risk for metabolic syndrome in patients with bipolar disorder and schizophrenia treated with secondgeneration antipsychotics. Bipolar Disord 2008;10:788-97
41. D'Mello DA, Narang S, Agredano G. Prevalence and Consequences of Metabolic Syndrome in Bipolar Disorder. Psychiatric Times 2007;24:1
42. Elmslie JL, Porter RJ, Joyce PR, Hunt PJ, Shand BI, Scott RS. Comparison of insulin resistance, metabolic syndrome and adiponectin in overweight bipolar patients taking sodium valproate and controls. Aust NZ J Psychiatry 2009;43:53-60
43. Fagiolini A, Frank E, Scott JA, Turkin S, Kupfer DJ. Metabolic syndrome in bipolar disorder: findings from the Bipolar Disorder Centre for Pennsylvanians. Bipolar Disord 2005;7:424-30
44. Fiedorowicz JG, Palagummi NM, Forman-Hoffman VL, Miller DD, Haynes WG. Elevated prevalence of obesity, metabolic syndrome, and cardiovascular risk factors in bipolar disorder. Ann Clin Psychiatry 2008;20:131-7
45. Garcia-Portilla MP, Saiz PA, Benabarre A, Sierra P, Perez J, Rodriguez A, et al. The prevalence of metabolic syndrome in patients with bipolar disorder. J Affect Disord 2008;106:197-201
46. Garcia-Portilla MP, Saiz PA, Bascaran MT, Martínez S, Benabarre A, Sierra P, et al. Cardiovascular risk in patients with bipolar disorder. J Affect Disord 2009;115:302-8
47. Gomes FA, Magalhaes PV, Kunz M, Da silveira LE, Weyne F, Andreazza AC, et al. Insulin resistance and metabolic syndrome in outpatients with bipolar disorder. Rev Psiq Clín 2010;37:81-4
48. González-Pinto A, Vieta E, Montes JM, Rejas-Gutiérrez J, Mesa F. Metabolic syndrome in patients with bipolar disorders (BD): Findings from the BIMET study European Psychiatry, Volume 24, Issue null, Page S600
49. Grover S, Aggarwal M, Chakrabarti S, Dutt A, Avasthi A, Kulhara P, et al. Prevalence of Metabolic syndrome in Bipolar Disorder: an exploratory study from North India. Prog Neuropsychiatry Neuropsychopharmacol 2012;36:141-6
50. Guerreiro DF, Navarro R, Telles-Correia D, Martins P, Trigo E, Silva M. Effectivity of screening, concepts and attitudes towards metabolic syndrome: A study in bipolar patients followed in hospital Santa Maria psychiatric consultation. Acta Med Port 2010;23:173-82
51. John AP, Koloth R, Dragovic M, Lim SC. Prevalence of metabolic syndrome among Australians with severe mental illness. Med J Aust 2009;190:176-9
52. Kemp DE, Calabrese JR, Tran QV, Pikalov A, Eudicone JM, Baker RA. Metabolic syndrome in patients enrolled in a clinical trial of aripiprazole in the maintenance treatment of bipolar I disorder: A post hoc analysis of a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2010;71:1138-44
53. Khatana SA, Kane J, Taveira TH, Bauer MS, Wu WC. Monitoring and prevalence rates of metabolic syndrome in military veterans with serious mental illness. PLoS One 2011;6:e19298
54. Lee NY, Kim SH, Cho B, Lee YJ, Chang JS, Kang UG, et al. Patients taking medications for bipolar disorder are more prone to metabolic syndrome than Korea's general population. Prog Neuropsychopharmacol Biol Psychiatry 2010;34:1243-9
55. Maina G, D'Ambrosio V, Aguglia A, Paschetta E, Salvi V, Bogetto F. Bipolar disorders and metabolic syndrome: A clinical study in 185 patients. Riv Psichiatr 2010;45:34-40
56. McIntyre RS, Woldeyohannes HO, Soczynska JK, Miranda A, Lachowski A, Liauw SS, et al. The rate of metabolic syndrome in euthymic Canadian individuals with bipolar I/II disorder. Adv Ther 2010;27:828-36
57. Rahman AH, Asmara HA, Baharudin A, Sidi H. Metabolic syndrome in psychiatric patients with primary psychotic and mood disorders. Asean J Psychiatry 2009;10:1-8
58. Salvi V, Albert U, Chiarle A, Soreca I, Bogetto F, Maina G. Metabolic syndrome in Italian patients with bipolar disorder. Gen Hosp Psychiatry 2008;30:318-23
59. Salvi V, D'Ambrosio V, Rosso G, Bogetto F, Maina G. Agespecific prevalence of metabolic syndrome in Italian patients with bipolar disorder. Psychiatry Clin Neurosci 2011;65:47-54
60. Gabriel-Sanchez R, Lorenzo-Carrascosa L, Arroyo MA, GonzRlez-Pinto A, Vieta E, Montes JM, et al. Metabolic syndrome in bipolar disorders in Spain: Findings from the population based case-control BIMET-VIVA study. Eur Neuropsychopharmacology 2009;19:S466
61. Sicras A, Rejas J, Navarro R, Serrat J, Blanca M. Metabolic syndrome in bipolar disorder: A cross-sectional assessment of a Health Management Organization database. Bipolar Disord 2008;10:607-16
62. Teixeira PJ, Rocha FL. The prevalence of metabolic syndrome among psychiatric inpatients in Brazil. Rev Bras Psiquiatr 2007;29:330-6
63. Van Winkel R, De Hert M, Van Eyck D, Hanssens L, Wampers M, Scheen A, et al. Prevalence of diabetes and the metabolic syndrome in a sample of patients with bipolar disorder. Bipolar Disord 2008;10:342-8
64. Van Winkel R, Van Os J, Celic I, Van Eyck D, Wampers M, Scheen A, et al. Psychiatric diagnosis as an independent risk factor for metabolic disturbances: Results from a comprehensive, naturalistic screening program. J Clin Psychiatry 2008;69:1319-27
65. Vuksan-Cusa B, Nadj S, Marcinko D, Jakovljevic M. Metabolic syndrome in patients with bipolar disorder. Eur Psychiatry 2008;23:S238-9
66. Vuksan-Cusa B, Marcinko D, Nad S, Jakovljević M. Differences in cholesterol and metabolic syndrome between bipolar disorder men with and without suicide attempts. Prog Neuropsychopharmacol Biol Psychiatry 2009;33:109-12
67. Vuksan-Cusa B, Sagud M, Jakovljević M. C-reactive protein and metabolic syndrome in patients with bipolar disorder compared to patients with schizophrenia. Psychiatr Danub 2010;22:275-7
68. Vuksan-Ćusa B, Jakovljević M, Sagud M, Mihaljević Peleš A, Marčinko D, Topić R, et al. Metabolic syndrome and serum homocysteine in patients with bipolar disorder and schizophrenia treated with SGA. Psychiatry Res 2011;189: 21-5
69. Yumru M, Savas HA, Kurt E, Kaya MC, Selek S, Savas E, et al. Atypical antipsychotics related metabolic Syndrome in bipolar patients. J Affect Disord 2007;98:247-52
70. Kim B, Kim S, McIntyre RS, Park HJ, Kim SY, Joo YH. Correlates of metabolic abnormalities in bipolar I disorder at initiation of acute phase treatment. Psychiatry Investig 2009;6:78-84
71. Sicras-Mainar A, Blanca-Tamayo M, Rejas-Gutiérrez J, Navarro-Artieda R. Metabolic syndrome in outpatients receiving antipsychotic therapy in routine clinical practice: A cross-sectional assessment of a primary health care database. Eur Psychiatry 2008;23:100-8
72. Rasgon NL, Kenna HA, Reynolds-May MF, Stemmle PG, Vemuri M, Marsh W, et al. Metabolic dysfunction in women with bipolar disorder: The potential influence of family history of type 2 diabetes mellitus. Bipolar Disord 2010;12:504-13
73. Moreno C, Merchán-Naranjo J, Alvarez M, Baeza I, Alda JA, Martínez-Cantarero C, et al. Metabolic effects of secondgeneration antipsychotics in bipolar youth: Comparison with other psychotic and nonpsychotic diagnoses. Bipolar Disord 2010;12:172-84
74. Chang HH, Yang YK, Gean PW, Huang HC, Chen PS, Lu RB. The role of valproate in metabolic disturbances in bipolar disorder patients. J Affect Disord 2010;124:319-23
75. Corman CL, Leung NM, Guberman AH. Weight gain in epileptic patients during treatment with valproic acid: A retrospective study. Can J Neurol Sci 1997;24:240-4
76. Garland EJ, Remick RA, Zis AP. Weight gain with antidepressants and lithium. J Clin Psychopharmacol 1988;8:323-30
77. Isojärvi JI, Laatikainen TJ, Knip M, Pakarinen AJ, Juntunen KT, Myllylä VV. Obesity and endocrine disorders in women taking valproate for epilepsy. Ann Neurol 1996;39:579-84
78. Nasrallah HA, Meyer JM, Goff DC, McEvoy JP, Davis SM, Stroup TS, et al. Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: Data from the CATIE schizophrenia trial sample at baseline. Schizophr Res 2006;86:15-22
79. Pylvänen V, Pakarinen A, Knip M, Isojärvi J. Insulin-related metabolic changes during treatment with valproate in patients with epilepsy. Epilepsy Behav 2006;8:643-8
80. Vestergaard P, Poulstrup I, Schou M. Prospective studies on a lithium cohort. 3. Tremor, weight gain, diarrhea, psychological complaints. Acta Psychiatr Scand 1988;78:434-41
81. Wu RR, Zhao JP, Jin H, Shao P, Fang MS, Guo XF, et al. Lifestyle intervention and metformin for treatment of antipsychoticinduced weight gain: A randomized controlled trial. JAMA 2008;299:185-93
82. Prossin A, McInnis M, Zalcman S, Ellingrod V. IL-6 is associated with metabolic syndrome in bipolar disorder. Brain Behavior Immunity 2010;24:S1-71
83. Kolotkin RL, Crosby RD, Corey-Lisle PK, Li H, Swanson JM. Performance of a weight-related measure of Quality of Life in a psychiatric sample. Qual Life Res 2006;15:587-96
84. Bond DJ, Lang DJ, Noronha MM, Kunz M, Torres IJ, Su W, et al. The association of elevated body mass index with reduced brain volumes in first-episode mania. Biol Psychiatry 2011;70:381-7